We hypothesized that sorafenib treatment dephosphorylated STAT3 and reduced MCL1 expression, promoting the binding of BECN1 with SLC7A11, and contributing to ferroptosis in HCC. This evidence concerns the gene BECN1 and hepatocellular carcinoma.